Lonza Group Ag (LZAGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...

Earnings Estimate Revisions for Lonza Group For the fiscal year ending December 2025, this company is expected to earn $1.87 per share, which is a change of 9.4% from the year-ago reported number. ...

Lonza Group AG on Friday backed its financial outlook for this year as sales and earnings rose strongly in the first half of 2022 thanks to good consumer demand. Sales totalled 2.98 billion Swiss ...

Lonza Group's (VTX:LONN) stock up by 4.7% over the past month. However, we decided to study the company's mixed-bag of fundamentals to assess what this could mean for future share prices ...

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate.

Access Lonza Group stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.

Lonza Group AG has selected Bank of America Corp. and Centerview Partners to arrange the sale of its capsules and health ingredients business, according to people familiar with the matter ...

There are no upcoming dividends for Lonza Group.The last dividend paid last dividend payout April 27, 2012 and was $0.21. Lonza Group has no upcoming dividends reported. The last reported dividend ...

Lonza Group Ag (LZAGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates ...

Lonza Group Ag (LZAGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...